Extract from M&A Insights

The below story was originally featured in our daily M&A Insights Newsletter. Selected stories, including this one, are posted to our website with some weeks of delay.
LEO Pharma acquires a minority stake in US-based PellePharm for DKK 457m
November 21, 2018

LEO Pharma and PellePharm have entered an agreement of collaboration to advance innovative therapies for rare skin diseases, a.o. Gorlin Syndrome. With the agreement, LEO Pharma acquires a minority stake and an option to acquire PellePharma for DKK 5bn is also agreed. The phase 3 trial regarding Gorlin Syndrome is essential to LEO’s acquisition. Stake size is not disclosed.

ⓘ This story was originally featured in our daily M&A Insights newsletter.
Our insights have been covered by: